SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : JNJ-Super company, Super stock! -- Ignore unavailable to you. Want to Upgrade?

To: Jerry Miller who wrote (436)7/19/2002 12:13:39 PM
From: Ausdauer  Read Replies (2) | Respond to of 552
 
"We've all mistaken asthma for passion, for too long."

Jerry, that sums it up nicely.

BTW, in the history of the market is this the first "Black Friday" we've ever seen?

Aus



To: Jerry Miller who wrote (436)9/26/2002 4:54:45 PM
From: Ausdauer  Respond to of 552
 
I think the Taxus II data needs to be interpreted...

...in light of the stent size and lesion complexity.

biz.yahoo.com

It will be interesting to hear some expert discussion on this matter.

Aus



To: Jerry Miller who wrote (436)9/26/2002 6:23:09 PM
From: Ausdauer  Respond to of 552
 
Taxus II vs. Ravel

The restenosis rates in the bare metal stents was higher in Ravel compared to
Taxus II. Also, nearly 20% of lesions treated with the Sirolimus-coated stents
were 2.5 mm in diameter, while Taxus II treated lesions 3.0 to 3.5 mm. This may
explain JNJ's performance today compared to BSX and GDT.

Aus


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News